Monopar Therapeutics (MNPR) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in 2025, including multiple ALXN1840 data presentations, a key publication, and leadership team expansion in preparation for a potential ALXN1840 launch.

• Strengthened balance sheet and advanced toward a planned NDA submission for ALXN1840 in Wilson disease.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025.

• Net loss for Q4 2025 was $5.2 million ($0.61/share), down from $10.9 million ($2.23/share) in Q4 2024.

• Net loss for full-year 2025 was $13.7 million ($1.85/share), compared to $15.6 million ($4.11/share) in 2024.

• R&D expenses for Q4 2025 were $3.9 million, down from $9.9 million in Q4 2024, mainly due to absence of one-time licensing costs.

• G&A expenses for Q4 2025 rose to $2.2 million from $1.2 million in Q4 2024, driven by higher personnel and legal costs.

Outlook and guidance

• Plans to submit NDA for ALXN1840 in Wilson disease in mid-2026 following recent FDA interactions.

• Current funds expected to support operations through at least December 31, 2027, covering regulatory, commercial, and R&D activities.